Cargando…
PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection
PfSPZ-CVac combines ‘PfSPZ Challenge’, which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x10(4) PfSPZ-CVac given 28 days apart had 100% vaccine efficacy (VE) against co...
Autores principales: | Murphy, Sean C., Deye, Gregory A., Sim, B. Kim Lee, Galbiati, Shirley, Kennedy, Jessie K., Cohen, Kristen W., Chakravarty, Sumana, KC, Natasha, Abebe, Yonas, James, Eric R., Kublin, James G., Hoffman, Stephen L., Richie, Thomas L., Jackson, Lisa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191919/ https://www.ncbi.nlm.nih.gov/pubmed/34048504 http://dx.doi.org/10.1371/journal.ppat.1009594 |
Ejemplares similares
-
PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial
por: Coulibaly, Drissa, et al.
Publicado: (2022) -
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines
por: Richie, Thomas L., et al.
Publicado: (2015) -
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection
por: Mordmüller, Benjamin, et al.
Publicado: (2022) -
Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial
por: Sulyok, Zita, et al.
Publicado: (2021) -
Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults
por: Jongo, Said Abdallah, et al.
Publicado: (2022)